Janssen Korea intensifies effort to boost sales

Published: 2004-01-28 06:56:00

Updated: 2004-01-28 06:56:00

Janssen Korea said recently that it would launch Velcade (bortezomib) injection, a new treatment for multiple myeloma, a cancer of the bone marrow, within this year in addition to Sporanox (itraconazole) for the treatment of fungal infections and Durogesic for the management of chronic intractabl...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK